Abstract
An oncogenic stimulus in a cell primarily results in hyperproliferation. However, uncontrolled cell proliferation is sensed by the cell and triggers a fail-safe mechanism resulting in senescence, apoptosis, or differentiation. This phenomenon is considered to be a cellular fail-safe mechanism to eliminate undesirable cells from a population of healthy cells. The RUNX1/AML1 gene, one of the most frequently targeted genes in human leukemia, is induced by the Ras oncogene in hematopoietic stem/progenitor cells and required to maintain the fail-safe mechanism. The stem cell pool is thereby protected from oncogenic insults and cancer-initiating cells, which would become cancer stem cells after accumulation of sequential genetic changes, are eliminated. This fail-safe mechanism and the consequence of its disruption in oncogenesis seems to be a fundamentally important concept, but have not been fully recognized to date. Gaining a better understanding of this mechanism might lead to new strategies to treat cancer stem cell-associated resistance to chemotherapy which is the subject of intense discussion in recent years.
Keywords: Runx, leukemia stem cell, cancer stem cell, senescence, apoptosis
Current Cancer Therapy Reviews
Title: Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Volume: 4 Issue: 3
Author(s): Lena Motoda, Motomi Osato and Yoshiaki Ito
Affiliation:
Keywords: Runx, leukemia stem cell, cancer stem cell, senescence, apoptosis
Abstract: An oncogenic stimulus in a cell primarily results in hyperproliferation. However, uncontrolled cell proliferation is sensed by the cell and triggers a fail-safe mechanism resulting in senescence, apoptosis, or differentiation. This phenomenon is considered to be a cellular fail-safe mechanism to eliminate undesirable cells from a population of healthy cells. The RUNX1/AML1 gene, one of the most frequently targeted genes in human leukemia, is induced by the Ras oncogene in hematopoietic stem/progenitor cells and required to maintain the fail-safe mechanism. The stem cell pool is thereby protected from oncogenic insults and cancer-initiating cells, which would become cancer stem cells after accumulation of sequential genetic changes, are eliminated. This fail-safe mechanism and the consequence of its disruption in oncogenesis seems to be a fundamentally important concept, but have not been fully recognized to date. Gaining a better understanding of this mechanism might lead to new strategies to treat cancer stem cell-associated resistance to chemotherapy which is the subject of intense discussion in recent years.
Export Options
About this article
Cite this article as:
Motoda Lena, Osato Motomi and Ito Yoshiaki, Runx1/AML1 is a Guardian of Hematopoietic Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294302
DOI https://dx.doi.org/10.2174/157339408785294302 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer
Current Pharmaceutical Design Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Topical Delivery of Antioxidants
Current Drug Delivery Processing of DNA Replication and Repair Intermediates by the Concerted Action of RecQ Helicases and Rad2 Structure-Specific Nucleases
Protein & Peptide Letters Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Psychosocial Vulnerability and Early Life Adversity as Risk Factors for Central Sensitivity Syndromes
Current Rheumatology Reviews Lifestyle Interventions for Cardiovascular Risk Reduction in Women with Breast Cancer
Current Cardiology Reviews Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study
Current Drug Targets Current Advances in Anti-Influenza Therapy
Current Medicinal Chemistry Novel Approaches to Anti-Inflammatory Agents as Therapeutics for Asthma
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews PPAR Ligands for Metabolic Disorders
Current Topics in Medicinal Chemistry Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine